DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/76x5rk/safinamide) has announced the addition of the "Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering.
In 2012, Newron completed Phase III clinical trials for safinamide, a dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck Serono (a division of Merck KGaA) had acquired the exclusive worldwide rights for safinamide; however, in 2011 the deal was terminated, seeing Merck returning the compound to Newron due to concerns over the potential market size for the drug.
- Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Safinamide including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Safinamide for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Brazil.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
For more information visit http://www.researchandmarkets.com/research/76x5rk/safinamide